{
    "nctId": "NCT02810704",
    "officialTitle": "Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement: Balancing Safety and Effectiveness",
    "inclusionCriteria": "1. 21 years of age or older;\n2. Undergoing elective primary, revision or second stage re-implantation total hip/knee replacement or uni-compartmental knee replacement or hip resurfacing arthroplasty;\n3. Has necessary mental capacity to participate and is able to comply with study protocol requirements;\n4. Eligible for randomization to at least two of the three study regimens;\n5. Is not pregnant on the day of surgery;\n6. Has signed the consent form; and\n7. Is willing to be randomized and participate in the study.\n* Must have minimum age of 21 Years",
    "exclusionCriteria": "1. Undergoing bilateral hip or knee replacement;\n2. Has been previously enrolled;\n3. Is pregnant or breastfeeding;\n4. Is on chronic anticoagulation other than antiplatelet medications;\n5. Concurrently enrolled in another active interventional clinical trial testing a drug or intervention known or believed to interact with aspirin, warfarin, or rivaroxaban;\n6. Has documented gastrointestinal, cerebral, or other hemorrhage within 3 months;\n7. Has a known diagnosis of defective hemostasis and past history of clinical bleeding requiring transfusion and treatment;\n8. Has had an operative procedure involving the eye, ear, or central nervous system within one month;\n9. Has uncontrolled hypertension with systolic BP \\> 220mmHg or diastolic BP \\> 120mmHg;\n10. Body weight of less than 41 kilograms at baseline visit;\n11. Member of a vulnerable patient population."
}